Juvenescence: Think aging up, rather than disease down
New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle.
Master Investor 2022: Our CEO, Dr. Greg Bailey, presents Juvenescence
The investment community is chasing a longer, healthier life like the rest of us.
The Simple Biotech Podcast: ‘Investing in the Longevity Industry: The Greatest Investment Opportunity in Human History’
What makes longevity one of the greatest investment opportunities in human history?
Juvenescence Chairman explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.
There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health
M2Bio Sciences Interview: Dr. Greg Bailey Goes Deep on Juvenescence, Longevity Biotech, and His Personal Story
Greg goes deep on Juvenescence, longevity biotech and his personal story.
BBC Science Focus Magazine: An End To Aging?
The human suffering is huge, and in the next 30 years, the number of over-65-year-olds is projected to double to 1.5 billion.
Forbes: AI And Optimism: Jim Mellon Wants Us All To Live Longer
Jim Mellon probably has a broader understanding of the progress being made confronting human aging than any other person alive.
Longevity Technology: ‘Greg Bailey on Democratizing Healthcare, Paradigm Shifts & Disruptive Technologies’
Dr. Bailey discusses the origins of Juvenescence as well as his belief that the nascent longevity industry is reaching an inflection point.
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.